News NICE relents and backs Kisqali for wide use in breast cancer Novartis' breast cancer therapy Kisqali has been cleared for NHS use in early breast cancer, an indication driving blockbuster sales of the drug.
News MSD, AZ partner LaNova bought by Sino Biopharm for $951m LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million.
News AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers.
Oncology On nuclear medicine and oncology, SHINE Technologies Greg Piefer, founder and CEO of SHINE Technologies, discusses nuclear medicine and the role of radiopharmaceuticals in oncology.
News NICE backs new drugs for Crohn's disease, lymphoma Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.
News Concentra throws lifeline to troubled CARGO Therapeutics After cutting staff and halting development of its CAR-T therapies, CARGO has agreed to a takeover by Kevin Tang's Concentra Bio.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.